Onconova announces successful end-of-phase 2 meeting with FDA for oral rigosertib
Onconova announced receipt of the End-of-Phase 2 meeting minutes from the FDA for the combination of oral rigosertib with azacitidine for the treatment of patients with HR-MDS. Based on these discussions, Onconova will design a randomized, controlled Phase 3 clinical trial. September 26, 2016